Special Instructions 014 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002

Closed Special Notice Posted

Not the latest version. See the latest special notice from .

Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
Washington, District of Columbia 20024, United States

Notice details come from SAM.gov. Updated .

About this opportunity

This Special Notice from the Department of Health and Human Services' Biomedical Advanced Research and Development Authority announces the addition of five new areas of interest to an existing Broad Agency Announcement for its DRIVe Easy Broad Agency Announcement. The new areas of interest seek submissions for home-based laboratory testing, digital health tools for pandemic preparedness, next-generation sequencing diagnostics, home-based over-the-counter SARS-CoV-2 diagnostics, and enabling technologies for home-based SARS-CoV-2 diagnostics.

The purpose of expanding the scope of the Broad Agency Announcement is to foster research and development opportunities that advance pandemic preparedness and diagnostic capabilities. Submissions are due between January 15, 2022 and February 3, 2023 depending on the area of interest. Eligible contractors can participate by submitting proposals for projects responsive to criteria in one of the new areas seeking technologies that meet sample type, performance, and regulatory approval standards. Multiple awards of up to $750,000 each are expected for submissions that qualify.

Notice text

Under these Special Instructions 014, BARDA is announcing the following as part of its EZ-BAA (BAA-20-100-SOL-0002):

  1. Close Area of Interest (AOI) #1 supporting the Early Notification to Act, Control, and Treat (ENACT) program.
  2. Pause AOI #7 supporting the ImmuneChip+ program until further notice.
  3. Add AOIs #8 #9, #10, and #11a and #11b to the EZ-BAA:
    • AOI #8:  Bringing Laboratory Testing to the Home
    • AOI #9:  Digital Health Tools for Pandemic Preparedness
    • AOI #10:  Next Generation Sequencing (NGS)-based Agnostic Diagnostic for Respiratory RNA Virus Pathogens
    • AOI #11a:Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2
    • AOI #11b:Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection

Files

File Type Posted
DRIVe EZ-BAA - Special Instructions 014.pdf PDF

Notice history

Notice Type Posted
Special Instructions 019 Issuance for Easy Broad Agency Announcement (EZ-BAA) Latest special notice Special Notice
Special Instructions 018 Issuance for Easy Broad Agency Announcement (EZ-BAA) Special Notice
Special Instructions 017 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Special Notice
Special Instructions 016 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Special Notice
Special Instructions 015 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Special Notice
This notice Special Notice
Special Instructions 013 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Special Notice
Esperovax Award Notice
Siemens Healthcare Diagnostics, Inc. Award Notice
Nanomix, Inc. Award Notice
Special Instructions 011 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Special Notice
Special Instructions 010 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Special Notice
Special Instructions 009 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Special Notice
Special Instructions 008 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Special Notice
Special Instructions 007 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002 Special Notice
Show 5 more

15 notices listed here. See the rest on GovTribe.

Similar open opportunities

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors